Announcements Trials
Browse Landscape

Phase

Phase 2 76Phase 3 42Phase 1/2 18Phase 1 18Phase 2/3 6Phase EARLY_PHASE1 2Phase 4 2Phase NA 1

Status

Active not recruiting 5Recruiting 1

Sponsor Class

NIH 2INDUSTRY 2OTHER 1NETWORK 1

Study Type

Interventional 6

Sponsor

Cancer Type

Lymphoid 6Other hematologic neoplasm 1

Conditions

Lymphoma, Large B-Cell, Diffuse 4Lymphoma 2Recurrence 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell, Marginal Zone 1Leukemia 1

Interventions

Cisplatin 22Magnetic Resonance Spectroscopy 18Gemcitabine 15Carboplatin 14pembrolizumab 13Specimen Handling 13Paclitaxel 13Radiotherapy 10Nivolumab 10Bevacizumab 10atezolizumab 8Radiation 8Platinum 8Pemetrexed 8Doxorubicin 8Docetaxel 81,2-diaminocyclohexaneplatinum II citrate 8Drug Therapy 7Dexamethasone 7Temozolomide 6Rituximab 6Radiotherapy, Intensity-Modulated 6Prednisone 6Surgical Procedures, Operative 5Ipilimumab 5Immunoglobulin G 5Disulfides 5Cytarabine 5Cyclophosphamide 5Biopsy 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2/3 × Rituximab × 90 days × Clear all
NCT05139017 2026-06-04

waveLINE-003

Merck Sharp & Dohme LLC

Phase 2/3 Recruiting
290 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT01046825 2026-06-02

Mature B-Cell Lymphoma And Leukemia Study III

St. Jude Children's Research Hospital

Phase 2/3 Active not recruiting
128 enrolled 12 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Lymphoma, Non-Hodgkin

NCT03984448 2026-05-29

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
363 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04799275 2026-05-13

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
422 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04442022 2026-05-06

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Karyopharm Therapeutics Inc

Phase 2/3 Active not recruiting
501 enrolled
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02405676 2026-03-19

BNHL-2015

Children's Cancer Group, China

Phase 2/3 Active not recruiting
200 enrolled
Lymphoid

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡